Altimmune, Inc. (ALT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. The company has not generated revenue from product sales and relies on equity financing and grants.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenues | $5,000 | $10,000 | $27,000 |
| Net Loss | $(24.64) million | $(49.03) million | $(36.14) million |
| Net Loss Per Share | $(0.35) | $(0.69) | $(0.72) |
| Operating Expenses | $26.75 million | $53.55 million | $39.79 million |
| Cash & Equivalents | $57.1 million (as of June 30, 2024) | ||
| Short-term Investments | |||
| Total Liquidity | $164.9 million (Cash + Investments) | ||
| Accumulated Deficit | $515.4 million |
Material Changes vs. Prior Period
- Revenue Decline: YTD revenue decreased 63% to $10,000 due to the closure of government contracts; remaining revenue consists of final indirect rate adjustments.
- Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by 36% compared to the prior year period, driven by higher R&D spend.
- R&D Expense Surge: R&D expenses increased 40% YTD to $42.6 million. This was primarily due to an $8.7 million increase in Q2 and a $16.3 million increase YTD related to the ramp-up of the IMPACT Phase 2b trial for MASH and increased manufacturing costs.
- HepTcell Wind-down: R&D expenses for the HepTcell program decreased significantly as the Phase 2 trial was deemed insufficient for further advancement in March 2024, leading to program termination.
- Stock-Based Compensation: G&A expenses increased due to a $1.0 million incremental stock-based compensation charge resulting from the modification of awards for the former CFO.
- Cash Position: Total cash and short-term investments decreased from $197.8 million at year-end 2023 to $164.9 million at June 30, 2024, reflecting a net cash burn of $78.0 million over the six-month period.
Outlook, Risks, and Contingencies
- Liquidity Outlook: Management believes current cash resources ($164.9 million) are sufficient to fund operations for at least the next 12 months. No shares were sold under the At-The-Market (ATM) program in Q2 2024; $60.6 million remains available under the ATM shelf.
- Clinical Updates:
- Pemvidutide: Full body composition results from the MOMENTUM Phase 2 obesity trial were presented in June 2024, showing 78.1% of weight loss derived from adipose tissue.
- HepTcell: Development stopped following insufficient Phase 2 results.
- Legal Proceedings:
- Class Action: A class action lawsuit (Mogan v. Altimmune) was filed in May 2024 alleging securities fraud regarding statements made between Dec 2023 and April 2024. A second similar complaint was filed in July 2024; actions are being consolidated.
- Derivative Action: A shareholder derivative suit (Stourbridge Investments LLC v. Garg) was filed in June 2024 alleging breaches of fiduciary duty and waste of corporate assets. A second similar suit was consolidated in July 2024.
- Commitments: The company has an obligation to pay up to $80.0 million in milestone payments to Spitfire Pharma, Inc., contingent on future product sales.
Investor Verification Checklist
- Verify the timeline and budget for the IMPACT Phase 2b trial ramp-up, which is the primary driver of increased R&D burn.
- Monitor the status of the consolidated class action and derivative lawsuits for potential settlement costs or management distraction.
- Assess the runway of $164.9 million against the projected cash burn rate, noting the cessation of ATM sales in Q2 2024.
- Review the lease renewal executed in May 2024, which extended the office/lab lease to 2030 and added $1.4 million in lease liabilities.
- Confirm the status of R&D incentive receivables ($2.6 million) as a potential source of near-term cash inflow.